Cargando…
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra2...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488545/ https://www.ncbi.nlm.nih.gov/pubmed/37685670 http://dx.doi.org/10.3390/jcm12175604 |
_version_ | 1785103500975276032 |
---|---|
author | Sidhu, Amanjot Khan, Nabeeha Phillips, Cameron Briones, Juan Kapoor, Anil Zalewski, Pawel Fleshner, Neil E. Chow, Edward Emmenegger, Urban |
author_facet | Sidhu, Amanjot Khan, Nabeeha Phillips, Cameron Briones, Juan Kapoor, Anil Zalewski, Pawel Fleshner, Neil E. Chow, Edward Emmenegger, Urban |
author_sort | Sidhu, Amanjot |
collection | PubMed |
description | Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra223-induced PSA flares on patient outcome. Using a retrospective cohort study of Ra223 treatment in four Ontario/Canada cancer centres, we identified 134 patients grouped into sub-cohorts according to distinct PSA response patterns: (i) initial PSA flare followed by eventual PSA decline; (ii) PSA response (≥30% PSA decrease within 12 weeks of treatment); and (iii) PSA non-response. We analyzed patient characteristics and outcome measures, including overall survival (OS), using the Kaplan-Meier method and log-rank testing. PSA flares were observed in 27 (20.2%), PSA responses in 11 (8.2%), and PSA non-responses in 96 (71.6%) patients. Amongst PSA flare patients, 12 presented with post-flare PSA decreases below baseline and 15 with PSA decreases below the flare peak but above baseline. Although only six flare patients achieved ≥30% PSA decreases below baseline, the median OS of all flare patients (16.8 months, 95% CI 14.9–18.7) was comparable to that of PSA responders and non-responders (p = 0.349). In summary, around 20% of mCRPC patients experience Ra223-induced PSA flares, whose outcome is similar to that of men with or without PSA responses. Further studies are needed regarding suitable biochemical surrogate markers of response to Ra223. |
format | Online Article Text |
id | pubmed-10488545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104885452023-09-09 Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer Sidhu, Amanjot Khan, Nabeeha Phillips, Cameron Briones, Juan Kapoor, Anil Zalewski, Pawel Fleshner, Neil E. Chow, Edward Emmenegger, Urban J Clin Med Article Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra223-induced PSA flares on patient outcome. Using a retrospective cohort study of Ra223 treatment in four Ontario/Canada cancer centres, we identified 134 patients grouped into sub-cohorts according to distinct PSA response patterns: (i) initial PSA flare followed by eventual PSA decline; (ii) PSA response (≥30% PSA decrease within 12 weeks of treatment); and (iii) PSA non-response. We analyzed patient characteristics and outcome measures, including overall survival (OS), using the Kaplan-Meier method and log-rank testing. PSA flares were observed in 27 (20.2%), PSA responses in 11 (8.2%), and PSA non-responses in 96 (71.6%) patients. Amongst PSA flare patients, 12 presented with post-flare PSA decreases below baseline and 15 with PSA decreases below the flare peak but above baseline. Although only six flare patients achieved ≥30% PSA decreases below baseline, the median OS of all flare patients (16.8 months, 95% CI 14.9–18.7) was comparable to that of PSA responders and non-responders (p = 0.349). In summary, around 20% of mCRPC patients experience Ra223-induced PSA flares, whose outcome is similar to that of men with or without PSA responses. Further studies are needed regarding suitable biochemical surrogate markers of response to Ra223. MDPI 2023-08-28 /pmc/articles/PMC10488545/ /pubmed/37685670 http://dx.doi.org/10.3390/jcm12175604 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sidhu, Amanjot Khan, Nabeeha Phillips, Cameron Briones, Juan Kapoor, Anil Zalewski, Pawel Fleshner, Neil E. Chow, Edward Emmenegger, Urban Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title_full | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title_fullStr | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title_full_unstemmed | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title_short | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer |
title_sort | prevalence and prognostic implications of psa flares during radium-223 treatment among men with metastatic castration resistant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488545/ https://www.ncbi.nlm.nih.gov/pubmed/37685670 http://dx.doi.org/10.3390/jcm12175604 |
work_keys_str_mv | AT sidhuamanjot prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT khannabeeha prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT phillipscameron prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT brionesjuan prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT kapooranil prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT zalewskipawel prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT fleshnerneile prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT chowedward prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer AT emmeneggerurban prevalenceandprognosticimplicationsofpsaflaresduringradium223treatmentamongmenwithmetastaticcastrationresistantprostatecancer |